# Boston Scientific

> Boston Scientific is a global medical-device company that designs and sells minimally invasive tools used by physicians to diagnose and treat cardiovascular, digestive, oncological, neurological and urological conditions. Founded in 1979 around the idea that catheters could replace more traumatic surgery, the company now reaches an estimated 48 million patients a year, operates through Cardiovascular and MedSurg segments, and earns revenue primarily from hospitals and healthcare providers that buy its devices, implants, disposable instruments and related systems.

- **Founded:** 1979
- **Headquarters:** Marlborough, United States
- **Founders:** John Abele (Co-founder), Peter Nicholas (Co-founder and founding CEO)
- **Team size:** Approximately 59,000 employees worldwide in 2025
- **Products:** FARAPULSE Pulsed Field Ablation System, WATCHMAN FLX Pro, AGENT Drug-Coated Balloon, LithoVue Elite, Asurys Fluid Management System
- **Notable:** Helped commercialize minimally invasive interventional medicine from its 1979 origins around Medi-Tech catheter technology., Reached an estimated 48 million patients in 127 countries in 2025., Generated $20.074 billion in 2025 net sales, up 19.9% as reported from 2024.

## Products & services

- **FARAPULSE Pulsed Field Ablation System** — A catheter-based platform that uses non-thermal electric fields to ablate cardiac tissue in patients with atrial fibrillation.
- **WATCHMAN FLX Pro** — A left atrial appendage closure implant intended to reduce stroke risk in eligible patients with non-valvular atrial fibrillation.
- **AGENT Drug-Coated Balloon** — A coronary balloon catheter that delivers an antiproliferative drug to treat in-stent restenosis.
- **LithoVue Elite** — A single-use digital flexible ureteroscope with intrarenal pressure monitoring for urinary tract procedures.
- **Asurys Fluid Management System** — An irrigation and distention system for endoscopic urology procedures that can respond to intrarenal pressure data when paired with LithoVue Elite.
- **WaveWriter Alpha Spinal Cord Stimulator** — An implantable neuromodulation system offering multiple therapy options for chronic pain.
- **EXALT Model D Single-Use Duodenoscope** — A disposable duodenoscope for ERCP procedures, designed to avoid the reprocessing challenges of reusable scopes.
- **AXIOS Stent and Electrocautery-Enhanced Delivery System** — An endoscopic system used to create a temporary conduit for drainage and other gastrointestinal interventions.
- **Cardiac Rhythm Management** — Pacemakers, defibrillators, cardiac monitoring and heart-failure technologies.
- **Interventional Oncology and Embolization** — Devices and therapies for image-guided embolization, tumor treatment and localized cancer care.

## Achievements

- Helped commercialize minimally invasive interventional medicine from its 1979 origins around Medi-Tech catheter technology.
- Reached an estimated 48 million patients in 127 countries in 2025.
- Generated $20.074 billion in 2025 net sales, up 19.9% as reported from 2024.
- Invested about $2.0 billion, or 10.2% of sales, in research and development in 2025.
- Launched roughly 100 products in 2025.
- Named to Fortune's America's Most Innovative Companies list in 2024.
- FARAPULSE received expanded U.S. labeling in 2025 for drug-refractory symptomatic persistent atrial fibrillation.
- The CHAMPION-AF study reported in 2026 that WATCHMAN FLX met all primary and secondary safety and efficacy endpoints.
- The SEISMIQ 4CE coronary intravascular lithotripsy pivotal trial met its primary safety and effectiveness endpoints in 2026.

## Latest updates

- **2026-07** — Reported second-quarter net sales of $5.442 billion, up 7.5% as reported and 7.0% organically year over year.
- **2026-07** — Disclosed a $1.5 billion investment for an approximately 34% stake in MiRus and an exclusive option on its TAVR business.
- **2026-05** — The SEISMIQ 4CE coronary intravascular lithotripsy catheter met primary safety and effectiveness endpoints in the FRACTURE IDE trial.
- **2026-03** — Received FDA 510(k) clearance for the Asurys Fluid Management System for endoscopic urology procedures.
- **2026-03** — Reported positive CHAMPION-AF results comparing WATCHMAN FLX with blood-thinner therapy for stroke-risk reduction.
- **2026-01** — Agreed to acquire Penumbra in a cash-and-stock transaction valued at approximately $14.5 billion enterprise value, subject to closing conditions.

## Links

- Website: https://www.bostonscientific.com
- LinkedIn: https://www.linkedin.com/company/boston-scientific
- Twitter/X: https://twitter.com/bostonsci
- YouTube: https://www.youtube.com/@bostonsci
- Instagram: https://www.instagram.com/bostonsci/
- Facebook: https://www.facebook.com/BostonScientific

---

Profile page: https://yespress.io/boston-scientific
Published by YesPress — https://yespress.io
Last updated: 2026-08-13